Innovax双价人乳头瘤病毒疫苗在9-14岁女孩中的安全性和免疫原性:一项3期临床试验的中期分析
在孟加拉国和加纳开展的3期试验中,1025名9-14岁女孩随机接种Cecolin双价HPV疫苗(0、6、12或24月间隔两剂,或一剂后24月接种另一剂)或Gardasil对照。中期分析显示0、6月程序Cecolin组100%血清阳性且非劣效于Gardasil,单剂后6月免疫原性与Gardasil相当,两疫苗安全性相似。
要点
- 0、6月程序Cecolin组接种第二剂后1月100%受试者ELISA血清阳性并发生血清转化。
- Cecolin 0、6月程序对Gardasil的非劣效性得到证明。
- 单剂后6月超过96%受试者对两种HPV抗原血清阳性,Cecolin组几何平均浓度有更高趋势。
核心结论
- Cecolin 0、6月程序诱导稳健免疫原性,接种第二剂后1月对Gardasil非劣效。
- 单剂后6月免疫原性与Gardasil相当,两疫苗均安全且耐受良好。
研究设计与样本
- 在孟加拉国和加纳开展的3期临床试验,1025名9-14岁女孩随机分组。
- 分组包括Cecolin 6、12或24月间隔两剂,一剂Gardasil后24月一剂Cecolin,或Gardasil 6月间隔两剂(对照)。
- 中期分析纳入0、6月程序两组,每组205名参与者。
主要发现
- 第二剂后1月,Cecolin组100%受试者ELISA血清阳性并对两种抗原血清转化。
- Cecolin对Gardasil的非劣效性得到证明。
- 单剂后6月,超过96%受试者对两种HPV抗原ELISA血清阳性,Cecolin组几何平均浓度有更高趋势。
- 两疫苗的反应原性和安全性相当。
关键数值与推荐
- 主要目标为Cecolin程序对对照在第二剂后1月的免疫非劣效性。
- 安全性终点包括接种后7天反应原性、30天非征集不良事件及全程严重不良事件。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: World Health Organization human papillomavirus (HPV) vaccination recommendations include a single- or two-dose schedule in individuals 9-20 years old and advice for generating data on single-dose efficacy or immunobridging. The ongoing Phase 3 trial of Innovax's bivalent (types 16 and 18) HPV vaccine (Cecolin®) assesses in low- and middle-income countries alternative dosing schedules and generates data following one dose in girls 9-14 years old. Interim data for the 6-month dosing groups are presented. METHODS: In Bangladesh and Ghana, 1,025 girls were randomized to receive either two doses of Cecolin at 6-, 12-, or 24-month intervals; one dose of Gardasil® followed by one dose of Cecolin at month 24; or two doses of Gardasil 6 months apart (referent). Serology was measured by enzyme-linked immunosorbent assay (ELISA) and, in a subset, by neutralization assays. Primary objectives include immunological non-inferiority of the Cecolin schedules to referent one month after the second dose. Safety endpoints include reactogenicity and unsolicited adverse events for 7 and 30 days post-vaccination, respectively, as well as serious adverse events throughout the study. RESULTS: Interim analyses included data from the two groups on a 0, 6-month schedule with 205 participants per group. One month after Dose 2, 100% of participants were seropositive by ELISA and had seroconverted for both antigens. Non-inferiority of Cecolin to Gardasil was demonstrated. Six months following one dose, over 96% of participants were seropositive by ELISA for both HPV antigens, with a trend for higher geometric mean concentration following Cecolin administration. Reactogenicity and safety were comparable between both vaccines. CONCLUSIONS: Cecolin in a 0, 6-month schedule elicits robust immunogenicity. Non-inferiority to Gardasil was demonstrated one month after a 0, 6-month schedule. Immunogenicity following one dose was comparable to Gardasil up to six months. Both vaccines were safe and well tolerated (ClinicalTrials.gov No. 04508309).
引用
- Zaman K, Schuind AE, Adjei S, et al. Safety and immunogenicity of Innovax bivalent human papillomavirus vaccine in girls 9-14 years of age: Interim analysis from a phase 3 clinical trial. Vaccine. 2024. PMID: 38431444. doi:10.1016/j.vaccine.2024.02.077
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。